Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report

Detalles Bibliográficos
Autores principales: Streicher, Caroline, Engalenc, Xavier, Gaudin, Marion, Vignaud, Guillaume, Daulange, Annick, Abraham, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502217/
https://www.ncbi.nlm.nih.gov/pubmed/32951190
http://dx.doi.org/10.1007/s40261-020-00969-5
_version_ 1783584179554877440
author Streicher, Caroline
Engalenc, Xavier
Gaudin, Marion
Vignaud, Guillaume
Daulange, Annick
Abraham, Bruno
author_facet Streicher, Caroline
Engalenc, Xavier
Gaudin, Marion
Vignaud, Guillaume
Daulange, Annick
Abraham, Bruno
author_sort Streicher, Caroline
collection PubMed
description
format Online
Article
Text
id pubmed-7502217
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-75022172020-09-21 Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report Streicher, Caroline Engalenc, Xavier Gaudin, Marion Vignaud, Guillaume Daulange, Annick Abraham, Bruno Clin Drug Investig Research Letter Springer International Publishing 2020-09-20 2020 /pmc/articles/PMC7502217/ /pubmed/32951190 http://dx.doi.org/10.1007/s40261-020-00969-5 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research Letter
Streicher, Caroline
Engalenc, Xavier
Gaudin, Marion
Vignaud, Guillaume
Daulange, Annick
Abraham, Bruno
Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title_full Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title_fullStr Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title_full_unstemmed Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title_short Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
title_sort could tocilizumab be an attractive therapeutic option for elderly patients with severe covid-19? a case report
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502217/
https://www.ncbi.nlm.nih.gov/pubmed/32951190
http://dx.doi.org/10.1007/s40261-020-00969-5
work_keys_str_mv AT streichercaroline couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport
AT engalencxavier couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport
AT gaudinmarion couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport
AT vignaudguillaume couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport
AT daulangeannick couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport
AT abrahambruno couldtocilizumabbeanattractivetherapeuticoptionforelderlypatientswithseverecovid19acasereport

Ejemplares similares